A Case of Suspected Adverse Reactions to Sirolimus in the Treatment of Generalized Lymphatic Anomaly
Joint Authors
Fujii, Takayuki
Shimono, Ryuichi
Tanaka, Aya
Katami, Hiroto
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-04-30
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Generalized lymphatic anomaly (GLA) is characterized by diffuse or multicentric proliferation of dilated lymphatic vessels resembling common lymphatic malformation, and thoracic lesions can be related to a poor prognosis.
Sirolimus, an inhibitor of the mammalian target of rapamycin, is effective against vascular anomalies with few severe adverse drug reactions.
Here, we report the case of a patient with intractable hemothorax pleural effusion due to GLA who was treated with sirolimus and experienced disseminated intravascular coagulation.
Although a standard treatment for GLA has not been established, pleural fluid might be reduced using the Kampo medicine Eppikajyutsuto.
American Psychological Association (APA)
Fujii, Takayuki& Shimono, Ryuichi& Tanaka, Aya& Katami, Hiroto. 2019. A Case of Suspected Adverse Reactions to Sirolimus in the Treatment of Generalized Lymphatic Anomaly. Case Reports in Pediatrics،Vol. 2019, no. 2019, pp.1-4.
https://search.emarefa.net/detail/BIM-1143666
Modern Language Association (MLA)
Fujii, Takayuki…[et al.]. A Case of Suspected Adverse Reactions to Sirolimus in the Treatment of Generalized Lymphatic Anomaly. Case Reports in Pediatrics No. 2019 (2019), pp.1-4.
https://search.emarefa.net/detail/BIM-1143666
American Medical Association (AMA)
Fujii, Takayuki& Shimono, Ryuichi& Tanaka, Aya& Katami, Hiroto. A Case of Suspected Adverse Reactions to Sirolimus in the Treatment of Generalized Lymphatic Anomaly. Case Reports in Pediatrics. 2019. Vol. 2019, no. 2019, pp.1-4.
https://search.emarefa.net/detail/BIM-1143666
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1143666